Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CBIONASDAQ:INFINASDAQ:MTEMNASDAQ:RGLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCatalyst Biosciences$0.77$0.19▼$8.69$291.29M1.05763,526 shs32,246 shsINFIInfinity Pharmaceuticals$0.07$0.01▼$0.01$726K1.632.58 million shs2.48 million shsMTEMMolecular Templates$0.00$0.00▼$1.59$1K1.534.58 million shsN/ARGLSRegulus Therapeutics$7.91+0.3%$4.32$0.83▼$8.20$547.64M0.49903,155 shs1.00 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCatalyst Biosciences0.00%0.00%0.00%0.00%0.00%INFIInfinity Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MTEMMolecular Templates0.00%0.00%0.00%-80.00%-99.99%RGLSRegulus Therapeutics+0.25%-0.50%+186.59%+481.62%+291.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBIOCatalyst BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AINFIInfinity PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/AN/AN/AN/ARGLSRegulus Therapeutics1.2914 of 5 stars2.13.00.00.03.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBIOCatalyst Biosciences 0.00N/AN/AN/AINFIInfinity Pharmaceuticals 0.00N/AN/AN/AMTEMMolecular Templates 0.00N/AN/AN/ARGLSRegulus Therapeutics 2.29Hold$8.507.46% UpsideCurrent Analyst Ratings BreakdownLatest MTEM, RGLS, INFI, and CBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$9.004/30/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/30/2025RGLSRegulus TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/30/2025RGLSRegulus TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$7.004/30/2025RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$28.00 ➝ $11.004/30/2025RGLSRegulus TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.00 ➝ $7.003/27/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$3.00 ➝ $6.003/17/2025RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/14/2025RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBIOCatalyst Biosciences$790K0.00N/AN/A($0.78) per share0.00INFIInfinity Pharmaceuticals$2.59M0.00N/AN/A($0.21) per share0.00MTEMMolecular Templates$23.48M0.00N/AN/A$0.78 per share0.00RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBIOCatalyst Biosciences-$8.24M-$1.38N/AN/AN/AN/A-364.68%-281.68%N/AINFIInfinity Pharmaceuticals-$44.37M-$0.46N/AN/AN/A-1,593.93%N/A-113.02%N/AMTEMMolecular Templates-$8.12M-$2.70N/AN/AN/A-61.35%-260.50%-46.90%N/ARGLSRegulus Therapeutics-$30.04M-$0.73N/AN/AN/AN/A-53.07%-48.58%8/14/2025 (Estimated)Latest MTEM, RGLS, INFI, and CBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025RGLSRegulus Therapeutics-$0.29-$0.15+$0.14-$0.15N/AN/A3/20/2025Q4 2024RGLSRegulus Therapeutics-$0.20-$0.20N/A-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBIOCatalyst BiosciencesN/AN/AN/AN/AN/AINFIInfinity PharmaceuticalsN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBIOCatalyst BiosciencesN/A2.882.88INFIInfinity PharmaceuticalsN/A1.651.65MTEMMolecular TemplatesN/A1.561.56RGLSRegulus TherapeuticsN/A14.1514.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBIOCatalyst Biosciences5.98%INFIInfinity Pharmaceuticals22.14%MTEMMolecular Templates95.47%RGLSRegulus Therapeutics92.38%Insider OwnershipCompanyInsider OwnershipCBIOCatalyst Biosciences2.92%INFIInfinity Pharmaceuticals9.81%MTEMMolecular Templates13.90%RGLSRegulus Therapeutics4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBIOCatalyst Biosciences737.98 million36.87 millionOptionableINFIInfinity Pharmaceuticals3090.76 million81.86 millionOptionableMTEMMolecular Templates2606.58 million5.67 millionNo DataRGLSRegulus Therapeutics3069.23 million62.65 millionOptionableMTEM, RGLS, INFI, and CBIO HeadlinesRecent News About These CompaniesBrokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $8.50May 28 at 1:51 AM | americanbankingnews.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of "Hold" from BrokeragesMay 26 at 3:07 AM | marketbeat.comVelan Capital Investment Management LP Makes New Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS)May 22, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Has $47,000 Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)May 21, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Earns Sell Rating from Analysts at StockNews.comMay 20, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Now Covered by Analysts at StockNews.comMay 19, 2025 | americanbankingnews.comLatham and Covington Advise on Novartis’s Acquisition of RegulusMay 16, 2025 | lawstreetmedia.comOctagon Capital Advisors LP Acquires 585,101 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)May 15, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.comMay 12, 2025 | marketbeat.comRegulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent UpdatesMay 9, 2025 | finanznachrichten.deRegulus Therapeutics Reports First Quarter 2025 Financial Results and Recent UpdatesMay 8, 2025 | prnewswire.comWhat is Leerink Partnrs' Estimate for RGLS Q1 Earnings?May 6, 2025 | marketbeat.comJPMorgan Chase & Co. Purchases 111,485 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)May 5, 2025 | marketbeat.comREGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLSMay 4, 2025 | businesswire.comNovartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion DealMay 4, 2025 | gurufocus.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Sees Large Decline in Short InterestMay 4, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Lowered to "Hold" Rating by Wells Fargo & CompanyMay 4, 2025 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Downgraded to "Hold" Rating by Leerink PartnrsMay 4, 2025 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Shares Sold by RA Capital Management L.P.May 3, 2025 | marketbeat.comRegulus Therapeutics (RGLS) Projected to Post Earnings on ThursdayMay 3, 2025 | marketbeat.comWells Fargo Downgrades Regulus Therapeutics (RGLS)May 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTEM, RGLS, INFI, and CBIO Company DescriptionsCatalyst Biosciences NASDAQ:CBIOCatalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.Infinity Pharmaceuticals NASDAQ:INFIInfinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.Molecular Templates NASDAQ:MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.Regulus Therapeutics NASDAQ:RGLS$7.91 +0.02 (+0.25%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$7.90 -0.01 (-0.18%) As of 05/27/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
